ナルミヤ コウスケ   NARUMIYA Kousuke
  成宮 孝祐
   所属   医学部 医学科(東京女子医科大学病院)
   職種   非常勤講師
論文種別 原著
言語種別 英語
査読の有無 査読あり
表題 Prognostic significance of six autoantibodies in esophageal squamous cell carcinoma: A prospective multi-institutional study.
掲載誌名 正式名:Annals of gastroenterological surgery
略  称:Ann Gastroenterol Surg
ISSNコード:24750328/24750328
掲載区分国内
巻・号・頁 9(4),pp.658-667
著者・共著者 SHIRATORI Fumiaki,FUJIWARA Naoto,NAKAJIMA Yasuaki,OTSUKA Koji,MURAKAMI Masahiko,MATSUDA Satoru,KAWAKUBO Hirofumi,TAKAHASHI Keita,TANISHIMA Yuichiro,OKA Daiji,ITO Shunichi,NARUMIYA Kosuke,ARAMAKI Osamu,TAKAYAMA Tadatoshi,SUZUKI Takashi,YAJIMA Satoshi,SHIMADA Hideaki
発行年月 2025/07
概要 AIM:Serum autoantibodies have been reported to react with tumor-associated antigens in various cancers. This study evaluated the diagnostic and prognostic significance of six autoantibody panels in esophageal squamous cell carcinoma.METHODS:In this study, 193 patients with esophageal squamous cell carcinoma and 78 healthy controls were enrolled. Serum antibodies were detected using originally developed enzyme-linked immunosorbent assays to detect autoantibodies against the following tumor antigens: c-myc, p62, RalA, p53, Sui1, and NY-ESO-1. The positive rates of the six-autoantibody panel were compared with those of SCC antigen (SCC-Ag). The prognostic significance of these autoantibodies was also evaluated.RESULTS:The overall positive rate was significantly higher in the six-autoantibody panel than in SCC-Ag (72% vs. 28%; p < 0.01). The positive rates of the six-autoantibody panel were 71% in stage 0/I, 73% in stage II, and 71% in stage III. No clinicopathological factors were associated with autoantibodies. Although the difference was not significant, the overall survival of the autoantibody-positive group was worse than that of the autoantibody-negative group (p = 0.14).CONCLUSION:The six-autoantibody panel was useful for detecting esophageal squamous cell carcinoma, particularly in stage 0/I; however, it showed limited prognostic significance.
DOI 10.1002/ags3.12910
PMID 40607289